An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth-Reference-Cited by-同舟云学术

An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth

Published:2015-04 Issue:281 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Kundu Parag¹²³,Genander Maria⁴,Strååt Klas⁴,Classon Johanna⁴,Ridgway Rachel A.⁵,Tan Ee Hong⁵,Björk Jan⁶,Martling Anna⁷,van Es Johan⁸,Sansom Owen J.⁵,Clevers Hans⁸,Pettersson Sven¹²³⁹,Frisén Jonas⁴

Affiliation:

1. Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden.

2. Singapore Centre on Environmental Life Sciences Engineering, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore.

3. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 637551, Singapore.

4. Department of Cell and Molecular Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden.

5. Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.

6. Center for Digestive Diseases, Karolinska Institute, SE-171 77 Stockholm, Sweden.

7. Department of Molecular Medicine and Surgery, Karolinska Institute, SE-171 77 Stockholm, Sweden.

8. Hubrecht Institute for Developmental Biology and Stem Cell Research and University Medical Centre Utrecht, Uppsalalaan 8, 3584CT Utrecht, Netherlands.

9. The National Cancer Centre, Singapore General Hospital, Singapore 169610, Singapore.

Abstract

The cAbl kinase inhibitor imatinib reduces intestinal tumor initiation and growth.

Funder

Torsten Soderbergs Stiftelse

Lee Kong Chian School of Medicine at Nanyang Technological University of Singapore

Swedish Cancer Society

Karolinska Institute

Knut och Alice Wallenbergs Stiftelse

Swedish Research Council

Singapore Millennium Foundation

Tobias Stiftelsen